Why Omeros Corporation’s (OMER) Stock Is Down 11.87%
As of Friday, October 16, Omeros Corporation’s OMER share price has dipped by 11.87%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Commentary & Analysis
Why Omeros Corporation’s (OMER) Stock Is Down 13.76%
As of Friday, October 16, Omeros Corporation’s OMER share price has dipped by 13.76%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Omeros Corporation’s (OMER) Stock Is Up 8.03%
As of Tuesday, September 22, Omeros Corporation’s OMER share price has surged by 8.03%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Omeros Corporation’s (OMER) Stock Is Up 5.13%
As of Thursday, September 17, Omeros Corporation’s OMER share price has surged by 5.13%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Omeros Corporation’s (OMER) Stock Is Up 5.47%
As of Wednesday, August 19, Omeros Corporation’s OMER share price has surged by 5.47%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | OMER | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,179.2 | $478.0 | 48% |
|
| Shares Out (Mil) | 89.6 | 42.8 | 60% |
|
| Institutional Ownership | 92.1% | 81.8% | 61% |
|
| Float (Mil) | 69.3 | 44.5 | 54% |
|
| Beta | 2.60 | 0.72 | 96% |
|
| Avg Daily Volume (000s) | 1,178 | 279 | 73% |
|
| Price Change (52-week) |
112.9% | 55.4% | 96% |
|
| Growth | OMER | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | 52.3% | (2.0%) | 94% |
|
| EPS (5yr) | 53.4% | 15.0% | 94 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (5.1%) | (15.1%) | 61% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.020) | $0.690 | $1.230 | |
| Month Ago EPS | ($0.020) | $0.690 | $1.230 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.310) | ($0.205) | $0.380 | |
| Year/Year Chg | (125.0%) | (1,008%) | (2,607%) | |
| Financials | OMER | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $38 | $392 | 18% |
|
| Net Income (TTM) (Mil) | $125 | ($11) | 63% |
|
| EPS (TTM) | $1.774 | ($0.700) | 69% |
|
| Operating Cash Flow (TTM) (Mil) | ($69) | ($7) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $0 | $5 | 43% |
|
| Long-Term Debt (Q1) (Mil) | $238 | $6 | 52% |
|
| Enterprise Value (Q1) (Mil) | $1,420 | $494 | 45% |
|
| Valuation | OMER | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.04 | na |
|
| P/E | 11.1 | 17.3 | 22% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.2 | 1.2 | 9% |
|
| Ratios | OMER | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 38.3% | 69.4% | 47% |
|
| Net Margin | 324.9% | 3.3% | 100% |
|
| ROA | 51.2% | (22.0%) | 99% |
|
| ROE | (89.2%) | (20.6%) | 10% |
|
| Liabilities to Assets | 117.9% | 32.2% | 97% |
|
| F-Score | 3 | 3 | 18% |
|
Omeros Corporation did not pass any screens on 10/26/2026.
